We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Theory Casts Doubt on Role of MYC-Specific Target Genes in Cancer Development

By LabMedica International staff writers
Posted on 09 Oct 2012
Breaking away from long held theories of how the MYC oncogene functions in many different types of cancers, a recent study found that when overexpressed, the c-Myc protein attached to the promoters and enhancers of all active genes massively amplify the active genes' output of proteins and mRNA.

MYC (v-myc myelocytomatosis viral oncogene homolog protein) is a transcription factor that activates expression of a great number of genes through binding on consensus sequences and recruiting histone acetyltransferases (HATs). More...
By acting as a transcriptional repressor in normal cells, MYC has a direct role in the control of DNA replication.

The MYC protein (c-Myc) is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis, and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement, and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias, and lymphomas, including Burkitt lymphoma.

The effect of high levels of c-Myc on global gene regulation has not been well understood but was widely thought to involve newly activated or repressed “Myc target genes.” Results reported in the September 28, 2012, issue of the journal Cell casts doubt on the existence of such Myc target genes.

Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) working with cancer cell cultures and mouse cancer models developed a new explanation for c-Myc activity. They suggested that in tumor cells expressing high levels of c-Myc the transcription factor accumulated in the promoter regions of active genes and caused transcriptional amplification. This amplification produced increased levels of transcripts within the cell’s gene expression program.

Amplification of all active genes rather than binding and regulating a new set of genes provides an explanation for the diverse effects of oncogenic c-Myc on gene expression in different tumor cells and suggests that transcriptional amplification overpowers the molecular signals that normally prevent tumor cell growth and proliferation.

"MYC is a key driver in most major cancers, but it has been notoriously difficult to drug," said senior author Dr. Richard Young, professor of biology at the Massachusetts Institute of Technology. "Now that we know the mechanism by which c-Myc acts, we can go after the components of that mechanism as potential drug targets. This research creates an even stronger impetus to find a way to drug the thing."

Related Links:
Massachusetts Institute of Technology



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.